SDC1 and Miyoshi myopathy: When tested on primary CD138+ plasma cells from newly diagnosed MM patients (Table S5), we also observed that combination of two BH3 mimetics and CFZ was the most effective in reducing viable cell number of malignant plasma cells (Figure 4B).